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Approximately 10% of melanoma cases are familial, but only 25–40% of familial melanoma
cases can be attributed to germ-line mutations in the CDKN2A – the most significant high-
risk melanoma susceptibility locus identified to date. The pathogenic mutation(s) in most
of the remaining familial melanoma pedigrees have not yet been identified.The most com-
mon mutations in nevi and sporadic melanoma are found in BRAF and NRAS, both of
which result in constitutive activation of the MAPK pathway. However, these mutations
are not found in uveal melanomas or the intradermal melanocytic proliferations known
as blue nevi. Rather, multiple studies report a strong association between these lesions
and somatic mutations in Guanine nucleotide-binding protein G(q) subunit alpha (GNAQ),
Guanine nucleotide-binding protein G(q) subunit alpha-11 (GNA11), and BRCA1-associated
protein-1 (BAP1). Recently, germ-line mutations in BAP1, the gene encoding a tumor sup-
pressing deubiquitinating enzyme, have been associated with predisposition to a variety
of cancers including uveal melanoma, but no studies have examined the association of
germ-line mutations in GNAQ and GNA11 with uveal melanoma and blue nevi. We have
now done so by sequencing exon 5 of both of these genes in 13 unique familial melanoma
pedigrees, members of which have had either uveal or cutaneous melanoma and/or blue
nevi. Germ-line DNA from a total of 22 individuals was used for sequencing; however no
deleterious mutations were detected. Nevertheless, such candidate gene studies and the
discovery of novel germ-line mutations associated with an increased MM susceptibility
can lead to a better understanding of the pathways involved in melanocyte transformation,
formulation of risk assessment, and the development of specific drug therapies.
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INTRODUCTION
Approximately 10% of melanoma cases are familial (Goldstein
and Tucker, 2001). However, only 25–40% of familial melanoma
cases can be specifically attributed to pathogenic germ-line muta-
tions in cyclin-dependant kinase inhibitor 2A (CDKN2A/p16) – the
most significant high-risk melanoma susceptibility gene identi-
fied to date (Goldstein and Tucker, 2001; Eliason et al., 2006;
Leachman et al., 2009). Two other genes, cyclin-dependant kinase 4
(CDK4) and alternate reading frame (ARF) have been confirmed
as additional high penetrance melanoma predisposition genes,
but account for less than 5% of hereditary melanoma families
worldwide (Leachman et al., 2009). GWAS analyses have identi-
fied several additional moderate and low-penetrance melanoma
predisposition genes but these contribute a small percentage to
the overall genetic risk (Amos et al., 2011). Therefore, the major-
ity of melanoma cases do not carry a known genetic mutation
that accounts for their increased risk of melanoma (Hayward,
2003).
The most common mutations in sporadic melanoma are those
of v-Raf murine sarcoma viral oncogene homolog B1 (BRAF)
and neuroblastoma RAS viral oncogene homolog (NRAS), both of
which result in constitutive activation of the MAPK pathway and
subsequent activation of pro-proliferative genes such as cyclin-
D1 (CCND1) (Onken et al., 2008). However, these mutations
do not characterize all melanocytic neoplasms or intradermal
melanocytic proliferations such as uveal melanoma and blue nevi,
respectively (Saldanha et al., 2004). Rather, multiple studies have
reported a strong association between these melanocytic lesions
and somatic guanine nucleotide-binding protein G(q) subunit alpha
(GNAQ), guanine nucleotide-binding protein G(q) subunit alpha-
11 (GNA11), and BRCA1-associated protein-1 (BAP1) mutations
in the absence of BRAF,NRAS, andKIT mutations (Harbour et al.,
2010; Van Raamsdonk et al., 2010). Recently, germ-line mutations
in BAP1, the gene encoding a tumor suppressing deubiquitinat-
ing enzyme, have been associated with predisposition to a variety
of cancers including uveal and cutaneous melanoma as well as
mesothelioma (Abdel-Rahman et al., 2011; Testa et al., 2011; Har-
bour, 2012; Wadt et al., 2012), but no studies have examined the
association of germ-line mutations in GNAQ and GNA11 with
uveal melanoma and blue nevi.
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GNAQ (OMIM ID 600998), found on chromosome 9q21, and
GNA11 (OMIM ID 139313), found on chromosome 19p13.3,
encode the G-protein α subunit of heterotrimeric GTP-binding
proteins and couple to the endothelin B receptor in melanocytes –
a required signaling pathway for melanocyte development (Dong
et al., 1995; Shin et al., 1999). The GNAQ and GNA11 mutations
associated with uveal melanoma and blue nevi occur almost exclu-
sively in exon 5 (most commonly Q209L; Figure 1) and involve
the glutamine residue within the ras-like domain, which plays an
essential role in the GTP hydrolysis activity of this gene’s protein
products (Van Raamsdonk et al., 2008, 2010). Activating GNAQ
and GNA11 mutations, such as those at codon 209, lock the
GTP-binding protein in their active, GTP-bound state resulting
in constitutive activation of the MAPK pathway in the absence
of BRAF and NRAS mutations (Van Raamsdonk et al., 2008).
In mice, these activating mutations ultimately function as onco-
genes resulting in proliferation of intradermal and transformed
melanocytes (Van Raamsdonk et al., 2004, 2008). These mouse
studies provide a genetic basis to help explain why intradermal
melanocytic proliferations affecting the conjunctiva and perior-
bital skin (nevi of Ota) are a risk factor for uveal melanoma (Van
Raamsdonk et al., 2008). The work of Van Raamsdonk et al. and
others suggest that mutations in GNAQ and GNA11 represent an
early event in the development of melanocytic tumors and may
contribute directly to the increased melanoma risk in hereditary
melanoma families that also have an increased incidence of uveal
melanoma and/or blue nevi.
We hypothesized that an increased melanoma risk in familial
melanoma families with uveal melanoma and/or blue nevi is due to
GNAQ and GNA11 germ-line mutations in exon 5 which result in
constitutive activation of the MAPK pathway. To test this hypoth-
esis, we investigated the frequency of GNAQ and GNA11 exon 5
germ-line mutations in 22 patients who had a personal history of
uveal melanoma and/or blue nevi from a total of 13 unique famil-
ial melanoma pedigrees previously identified as being high-risk
for the development of melanoma.
MATERIALS AND METHODS
STUDY SUBJECTS
Through the Familial Melanoma Research Clinic at the Huntsman
Cancer Institute, we identified 22 study subjects who had a
personal history of uveal melanoma and/or blue nevi and were
also members of a pedigree with familial melanoma (defined as
≥2 first-degree relatives with a history of melanoma or pancre-
atic cancer or ≥3 family member with a history of melanoma
of any relationship) (Supplementary Material). This study was
approved by the University of Utah’s Institutional Review Board
(IRB# 7616), which also acts as the University’s Ethical Review
Board.
NUCLEIC ACID ISOLATION AND PCR AMPLIFICATION
From each of the 22 study subjects, archived DNA for genetic
analysis was obtained using peripheral whole blood collected in
Acid Citrate Dextrose (ACD) Venous Blood Vacuum Collection
Tubes. Genomic DNA was isolated using Gentra Puregene Kit
(Qiagen Inc.). DNA purity and concentration was determined
using the NanoDrop 2000 Spectrophotometer (Thermo Scien-
tific). PCR amplification of exon 5 of GNAQ and GNA11 was
performed using HotStarTaq DNA Polymerase (Qiagen Inc.) with
the primers listed in Table 1. All PCR primers were designed and
purchased from the University of Utah’s DNA Sequencing and
Genomics Core Facility. For all PCR reactions, 1µL of genomic
DNA [50 ng/µL] was used as a PCR template in 20µL total reac-
tion volume containing 2µL 10× PCR Buffer (Denville Scientific,
Inc.), 1.6µL 2.5 mM dNTP Mix (Invitrogen), 1µL of each forward
and reverse primer [10 mM], 13.2µL H2O, and 0.2µL Hot-Start
Taq (5 U/mL) (Denville Scientific, Inc.). The conditions for PCR
amplification were 95°C for 5 min followed by 35 cycles of 95°C for
15 s, 60°C for 20 s, and 72°C for 20 s. Following amplification, 3µL
of product and 1µL of 1 kb Plus DNA Ladder (Invitrogen) were
loaded and run on 1% agarose gels at 100 V for 30 min and DNA
bands were visualized on a UV transilluminator after ethidium
bromide staining. All PCR products where then purified using
the ExoSAP-IT PCR Cleanup Protocol (Affymetrix/USB). PCR
products where then purified using the ExoSAP-IT PCR Cleanup
Protocol (Affymetrix/USB).
GENETIC ANALYSIS OF STUDY SUBJECTS
The University of Utah’s DNA Sequencing and Genomics Core
Facility performed sequencing reactions in both directions
using Big Dye Terminator chemistry on an ABI Prism 3700
DNA analyzer. Sequences were aligned and analyzed for single
FIGURE 1 | Most common activating exon 5 GNAQ and GNA11 gene mutations.
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Table 1 | PCR primers used for the mutation profiling of GNAQ,
GNA11, and BAP1.
Gene Exon Forward primer
sequence 5′–3′
Reverse primer
sequence 5′–3′
GNAQ 5 TTTCCCTAAGTTTGTAAGTAGTGCT AAGTTCACTCCATT
CCCCAC
GNA11 5 AGCCGATGTCAGTCTGGTGT AAGGCAGAGGGAAT
CAGAGG
BAP1 4 AGTGATGACGCAGTGCAAAG CTCCATTTCCACTT
CCCAAG
5 TGTCCAGATATGACTGACCTG ATGTGGTAGCATTCC
CAGTG
6–7 TCTGAAGCTTTGCCTTCCAC GCCACTGGGTACCA
CATACC
8 TGTCTTCCTTCCCACTCCTG TGGATACTCTCTGT
CCCTCCC
9 CTCAACCTGATGGCGGG AATGCAGGGAGGG
TTGG
10 TTCCTTTAGGTCCTCAGCCC AAAAGACTTTCCCT
GTTTAGG
11 TCTCTGGGAAGTGCTGGTTC CATGGGAAAATTGC
CTGTTG
12 CCGAGCAGCACTTGTTTG GATCCGAAGCACCT
AGAACC
13 AGCCATTCTGGGTACTGCTG GAGTGCAGGACAC
TTTGTGG
15–16 CTGCCTATTGCTCGTGGG CAAGGTCTGCTCA
AGCCTC
17 ACAGGGAGGGCCATGAG TACTGGGAAAAGG
GGAAGTG
nucleotide polymorphisms and/or mutations with respect to pub-
lished reference sequences found in the UCSC Genome Browser
using Sequencher 4.5 software (Ann Arbor, MI, USA). Analysis
of CDKN2A was performed by sequencing the 3 exons plus 95
non-coding base pairs of p16 (Myriad Genetics, Salt Lake City,
UT, USA), as well as exon 1-beta which codes for a portion of p14
ARF (Gene Dx, Gaithersburg, MD, USA). CDK4 analysis was car-
ried out by sequencing exon 2 and flanking splice sites (Gene Dx,
Gaithersburg, MD, USA).
RESULTS
Of these 22 study subjects (Table 2), 14 had a personal history of
cutaneous melanoma, 3 had a personal history of uveal melanoma
(although there are four pedigrees that have individuals with uveal
melanoma), 13 had a personal history of blue nevi, and 5 had a
personal history of cutaneous melanoma as well as blue nevi. The
22 study subjects were from a total of 13 unique familial melanoma
pedigrees (Supplementary Material). Of the 22 samples studied, all
were wild-type at exon 5 for both GNAQ and GNA11. The results
collected from this subset of high-risk melanoma families indi-
cate that the inherited risk observed in these hereditary melanoma
families is not due to activating germ-line mutations in exon 5 of
GNAQ and GNA11.
The studied pedigrees were previously determined to lack
germ-line mutations in CDKN2A, p16, ARF, and CDK4, with the
exception of three pedigrees for which sequencing data could not
be obtained. These sequencing results are listed in Table 2. Addi-
tionally, screening for BAP1 mutations in exons 9 and 12 was
performed on all 22 study subjects. Sequencing of exons 4–13 and
15–17 of BAP1 was performed on Study Subjects 3 (pedigree C)
and 7 (pedigree G), both of whom had a personal history of uveal
and cutaneous melanoma. In all instances, no BAP1 mutations
were found.
DISCUSSION
Malignant melanoma is a devastating malignancy for which few
effective targeted treatments (e.g., BRAF inhibitors) are avail-
able. The major aim of the current investigation was to deter-
mine whether or not germ-line mutations in exon 5 of GNAQ
and GNA11 represent an early event in the development of
melanocytic tumors and/or potential genetic biomarkers asso-
ciated with the increased melanoma risk observed in hereditary
melanoma families that lack other known pathogenic germ-line
mutations. The lack of GNAQ and GNA11 germ-line mutations
in familial melanoma pedigrees with an increased incidence of
uveal melanoma and blue nevi further is supportive of the impor-
tance of sporadic mutations in these genes in blue nevi and uveal
melanoma as previously published. Nevertheless, the functional
consequence of activating GNAQ and GNA11 mutations on the
MAPK pathway highlights an important concept: that specific gene
mutations may result in an alternate route of MAPK pathway acti-
vation and subsequent melanocyte proliferation in the absence
of more common gene mutations such as those in BRAF, NRAS,
and KIT.
The major limitation of this study is the small sample size
and limited number of familial melanoma pedigrees (n= 13)
and uveal melanoma cases (n= 4). Therefore, it is necessary that
further studies be done and our hypothesis be considered in
a larger sample size before any final conclusion can be drawn.
However, to our knowledge, this is one of the largest studies
to date looking specifically at germ-line mutations in familial
melanoma pedigrees with uveal melanoma and/or blue nevi. This
study is also a retrospective study and is not designed to eluci-
date the complex interaction between specific gene mutations,
phenotype characteristics, and MM susceptibility. Additionally,
this study is not a complete survey of all of the genes thought
to confer an increased familial melanoma risk and the screen-
ing for germ-line mutations in CDKN2A, p16, ARF, CDK4, and
BAP1 was incomplete. Subsequent studies are therefore neces-
sary to determine the genetic basis for the increased risk of
MM seen in the families included in this study. Finally, our
study was limited to exon 5 of GNAQ and GNA11. It is, how-
ever, possible that an activating mutation outside of the ras-like
domain may be present in the families we studied though this is
unlikely given that activating mutations are found almost exclu-
sively in exon 5 as mentioned above (Van Raamsdonk et al., 2008,
2010).
In summary, we report the absence of germ-line mutations
in exon 5 of GNAQ and GNA11 in familial melanoma pedi-
grees with an increased incidence of uveal melanoma and/or blue
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nevi. Melanoma’s high incidence and poor treatment outcomes
as well as the high number of familial melanoma cases lacking
known pathogenic germ-line mutations, underscores the impor-
tance of future studies using a candidate gene approach when
phenotypic annotation is available. Such candidate gene studies
and the discovery of novel germ-line mutations associated with
an increased MM susceptibility can lead to a better understanding
of the pathways involved in melanocyte transformation, formu-
lation of risk assessment, and the development of specific drug
therapies. Additionally, our study not only shows that our families
don’t have known genetic mutations accounting for their increased
melanoma risk, but also suggests that the genetic cause of familial
ocular melanoma and blue nevi is yet to be discovered and that fur-
ther investigation of these families could lead to identification of
new targets for ocular melanoma. Further, a better understanding
of the genetic basis observed in the inherited risk associated with
familial melanoma may yield insights into the molecular patho-
genesis of sporadic melanoma and, ultimately, improved methods
of detection and treatment.
ACKNOWLEDGMENTS
The Tom C. Mathews Familial Melanoma Research Clinic, the
Huntsman Cancer Foundation, the Cancer Center Support Grant
for the University of Utah (5P30CA042014-23), the Melanoma
Research Foundation (MRF), and the University of Utah’s NIH
Medical Student Summer Research Program for their funding sup-
port. Research was also supported by the Utah Cancer Registry,
which is funded by Contract No. HHSN261201000026C from the
National Cancer Institute’s SEER Program with additional support
from the Utah State Department of Health and the University of
Utah. Utah Population Database (UPDB) and Huntsman Cancer
Institute Staff for pedigree identification and pedigree prepara-
tion. The University of Utah’s DNA Sequencing and Genomics
Core Facility for their technical assistance.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: http://www.frontiersin.org/Cancer_Genetics/10.3389/
fonc.2013.00160/abstract
REFERENCES
Abdel-Rahman, M. H., Pilarski, R.,
Cebulla, C. M., Massengill, J. B.,
Christopher, B. N., Boru, G., et al.
(2011). Germline BAP1 mutation
predisposes to uveal melanoma,
lung adenocarcinoma, meningioma,
and other cancers. J. Med. Genet. 48,
856–859. doi:10.1136/jmedgenet-
2011-100156
Amos, C. I., Wang, L. E., Lee, J. E., Ger-
shenwald, J. E., Chen, W. V., Fang, S.,
et al. (2011). Genome-wide associa-
tion study identifies novel loci pre-
disposing to cutaneous melanoma.
Hum. Mol. Genet. 20, 5012–5023.
doi:10.1093/hmg/ddr415
Dong, Q., Shenker, A., Way, J., Had-
dad, B. R., Lin, K., Hughes, M. R.,
et al. (1995). Molecular cloning of
human G alpha q cDNA and chro-
mosomal localization of the G alpha
q gene (GNAQ) and a processed
pseudogene. Genomics 30, 470–475.
doi:10.1006/geno.1995.1267
Eliason, M. J., Larson, A. A., Flo-
rell, S. R., Zone, J. J., Cannon-
Albright, L. A., Samlowski, W.
E., et al. (2006). Population-based
prevalence of CDKN2A mutations
in Utah melanoma families. J.
Invest. Dermatol. 126, 660–666.
doi:10.1038/sj.jid.5700094
Goldstein, A. M., and Tucker, M. A.
(2001). Genetic epidemiology of
cutaneous melanoma. Arch. Derma-
tol. 137, 1493–1496.
Harbour, J. W. (2012). The genet-
ics of uveal melanoma: an emerg-
ing framework for targeted ther-
apy. Pigment Cell Melanoma Res.
25, 171–181. doi:10.1111/j.1755-
148X.2012.00979.x
Harbour, J. W., Onken, M. D., Roberson,
E. D. O., Duan, S., Cao, L., Worley,
L. A., et al. (2010). Frequent muta-
tion of BAP1 in metastasizing uveal
melanomas. Science 330, 1410–1413.
doi:10.1126/science.1194472
Hayward, N. K. (2003). Genetics
of melanoma predisposi-
tion. Oncogene 22, 3053–3062.
doi:10.1038/sj.onc.1206445
Leachman, S. A., Carucci, J., Kohlmann,
W., Banks, K. C., Asgari, M. M.,
Bergman, W., et al. (2009). Selection
criteria for genetic assessment of
patients with familial melanoma. J.
Am. Acad. Dermatol. 61, 677.e1–e14.
doi:10.1016/j.jaad.2009.03.016
Onken, M. D., Worley, L. A., Long, M.
D., Duan, S., Council, M. L., Bow-
cock, A. M., et al. (2008). Onco-
genic mutations in GNAQ occur
early in uveal melanoma. Invest.
Ophthalmol. Vis. Sci. 49, 5230–5234.
doi:10.1167/iovs.08-2145
Saldanha, G., Purnell, D., Fletcher, A.,
Potter, L., Gillies, A., and Pringle,
J. H. (2004). High BRAF muta-
tion frequency does not char-
acterize all melanocytic tumor
types. Int. J. Cancer 111, 705–710.
doi:10.1002/ijc.20325
Shin, M. K., Levorse, J. M., Ingram, R.
S., and Tilghman, S. M. (1999). The
temporal requirement for endothe-
lin receptor-B signalling during
neural crest development. Nature
402, 496–501. doi:10.1038/99
0040
Testa, J. R., Cheung, M., Pei, J., Below,
J. E., Tan, Y., Sementino, E., et al.
(2011). Germline BAP1 mutations
predispose to malignant mesothe-
lioma. Nat. Genet. 43, 1022–1025.
doi:10.1038/ng.912
Van Raamsdonk, C. D., Bezrookove,
V., Green, G., Bauer, J., Gau-
gler, L., O’Brien, J. M., et al.
(2008). Frequent somatic mutations
of GNAQ in uveal melanoma and
blue naevi. Nature 457, 599–602.
doi:10.1038/nature07586
Van Raamsdonk, C. D., Fitch, K. R.,
Fuchs, H., De Angelis, M. H.,
and Barsh, G. S. (2004). Effects
of G-protein mutations on skin
color. Nat. Genet. 36, 961–968.
doi:10.1038/ng1412
Van Raamsdonk, C. D., Griewank,
K. G., Crosby, M. B., Garrido,
M. C., Vemula, S., Wiesner,
T., et al. (2010). Mutations in
GNA11 in uveal melanoma. N.
Engl. J. Med. 363, 2191–2199.
doi:10.1056/NEJMoa1000584
Wadt, K., Choi, J., Chung, J.-Y.,
Kiilgaard, J., Heegaard, S.,
Drzewiecki, K. T., et al. (2012).
A crypticBAP1splice mutation in
a family with uveal and cutaneous
melanoma, and paraganglioma.
Pigment Cell Melanoma Res.
25, 815–818. doi:10.1111/pcmr.
12006
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or financial relationships that
could be construed as a potential con-
flict of interest.
Received: 28 February 2013; accepted:
04 June 2013; published online: 28 June
2013.
Citation: Hawkes JE, Campbell J, Garvin
D, Cannon-Albright L, Cassidy P and
Leachman SA (2013) Lack of GNAQ
and GNA11 germ-line mutations in
familial melanoma pedigrees with uveal
melanoma or blue nevi. Front. Oncol.
3:160. doi: 10.3389/fonc.2013.00160
This article was submitted to Frontiers in
Cancer Genetics, a specialty of Frontiers
in Oncology.
Copyright © 2013 Hawkes, Campbell,
Garvin, Cannon-Albright , Cassidy and
Leachman. This is an open-access arti-
cle distributed under the terms of the
Creative Commons Attribution License,
which permits use, distribution and
reproduction in other forums, provided
the original authors and source are cred-
ited and subject to any copyright notices
concerning any third-party graphics etc.
www.frontiersin.org June 2013 | Volume 3 | Article 160 | 5
